A UK-based developer of drugs to treat respiratory diseases
Enterprise Therapeutics has raised $33.1M in total funding. The most recent round was Series B. The last funding was announced in January 2024.
Enterprise Therapeutics's investors include Versant Ventures, Panakes Partners, Forbion Capital Partners, IP Group, Novartis Venture Fund.
Enterprise Therapeutics is headquartered in Falmer, United Kingdom.
A UK-based developer of drugs to treat respiratory diseases
Enterprise Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Enterprise Therapeutics — Funding & Investors." VCBacked, January 29, 2024, https://www.vcbacked.co/company/enterprise-therapeutics. Accessed September 14, 2026.
VCBacked. (2024). Enterprise Therapeutics — Funding & Investors. Retrieved September 14, 2026, from https://www.vcbacked.co/company/enterprise-therapeutics
{{cite web |title=Enterprise Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/enterprise-therapeutics |website=VCBacked |access-date=September 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated